Patent · US Active

Method for controlling fibrosis and other pathological deposits in tissues comprising administering a GHRP-6 composition

US8722626B2 · kind B2 · utility

1Cited by
1References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 1, 2011
Grant dateMay 13, 2014
Priority date
Expiry dateNov 8, 2031

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.